Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company"), announces that it has filed the formal request to the European Medicines Agency (EMEA) for re-examination of its marketing authorization application (MAA) for Cerepro ®, Ark's novel gene-based therapy for operable malignant glioma (brain cancer)... ... more
Tags: cerepro, examination,

Keywords: Cancer / Oncology news, medical news, health news, medical headlines, healthcare news, health articles, medicine articles, welfare, living

Description: Ark Therapeutics Group plc (AKT: LSE) (Ark or the Company), announces that it has filed the formal request to the European Medicines Agency (EMEA) for re-examination of its marketing authoriza